The DFA Discussion, page-81

Hey Ollie. Obviously Opthea is damaged . However, unblinding a trial that’s over 80 percent done isn’t unusual, especially if it’s a way to salvage something. It doesn’t make the data useless. It just needs to be handled properly with the right stats and oversight. The FDA would be involved anyway.Plenty of trials have been unblinded late and still ended up approved or licensed. MST and Regal (as a 30% shareholder) will navigate a path forward to preserve value. VA is not guaranteed. It all comes down to what the ShORe data shows. So let’s wait for that. Hopefully we know more on Monday. Take care.